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Abstract: 
Objectives: The objective of this study was to investigate differences in the diagno-
sis and management of systemic lupus erythematosus (SLE) by primary care and special-
ist physicians in a population-based registry. 
Methods: This study includes individuals from the 2009 Indian Health Service lupus 
registry population with a diagnosis of SLE documented by either a primary care pro-
vider or specialist. SLE classification criteria, laboratory testing, and medication 
use at any time during the course of disease were determined by medical record ab-
straction. 
Results: Of the 320 individuals with a diagnosis of SLE, 249 had the diagnosis docu-
mented by a specialist, with 71 documented by primary care. Individuals with a spe-
cialist diagnosis of SLE were more likely to  have medical record documentation of 
meeting criteria for SLE by all criteria sets (ACR, 79% vs 22%; Boston Weighted, 82% 
vs 32%; and Systemic Lupus International Collaborating Clinics (SLICC), 83% vs 35%; p 
<0.001 for all comparisons). In addition, specialist diagnosis was associated with 
documentation of ever having been tested for anti-double stranded DNA antibody and 
complement C3 and C4 (p<0.001). Documentation of ever receiving hydroxychloroquine was 
also more common with specialist diagnosis (86% vs 64%, p<0.001). 
Conclusions: Within the population studied, specialist diagnosis of SLE was associated 
with a higher likelihood of having SLE classification criteria documented, being test-
ed for biomarkers of disease, and ever receiving treatment with hydroxychloroquine.  
These data support efforts both to increase specialist access for patients with sus-
pected SLE and to provide lupus education to primary care providers. 
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INTRODUCTION 
Systemic lupus erythematosus (SLE) is an autoimmune disease with a variable clinical 
presentation as well as complex classification criteria that include many different 
organ systems.1 The diagnosis of SLE may be challenging even for clinicians experi-
enced with the disease, and is based on laboratory findings coupled with characteris-
tic clinical features. Validation of the diagnosis of SLE in research is performed us-
ing classification criteria. The 1982 American College of Rheumatology (ACR) revised 
classification criteria for SLE, updated in 1997,2 were developed for high specifici-
ty, excluding patients with limited disease. The Boston Weighted criteria were created 
to increase classification sensitivity in epidemiological studies.3 The Systemic Lupus 
International Collaborating Clinics (SLICC) Classification criteria, published in 
2012, were developed to better capture the broader spectrum of immunologic and clini-
cal conditions characteristic of SLE.4 Although these classification criteria sets 
were designed for use in research, the signs and symptoms in these criteria are also 
used in the clinical diagnosis of SLE. 
 
Prior research suggests that primary care and specialist physicians differ in their 
management of SLE.5,6  SLE guidelines developed by the ACR in 19997 highlight the role 
of primary care providers in facilitating early diagnosis  as well as follow-up of 
stable or mild SLE while working in collaboration with a specialist.  More recent SLE 
guidelines8,9 and quality indicators10,11 designed primarily for a specialist audience 
focus on optimal diagnosis and management of SLE or lupus nephritis.  Quality indica-
tors developed in the US and Europe include a broad range of topics related to the 
care of SLE.10,11 With respect to laboratory testing, both sets of quality indicators 
recommend testing for autoantibodies, complement, and urinalysis. Given its effective-
ness in controlling skin and joint disease as well as reduction of damage in renal and 
non-renal SLE, hydroxychloroquine is considered first-line therapy in the management 
of all patients with SLE.12-14 Although primary care-specific guidelines for SLE have 
not been developed, the primary care literature contains some reviews and recommenda-
tions for primary care diagnosis and management of SLE in alignment with the 1999 ACR 
guidelines and others.15,16 
 
Regional differences in the number of rheumatologists, as well as a general shortage 
of practicing rheumatologists, may make de facto specialist diagnosis and management 
of every individual with SLE challenging.17,18 Higher SLE prevalence in racial/ethnic 
minority populations such as the American Indian/Alaska Native (AI/AN) and First Na-
tions populations in the US and Canada,19,20 which are often located in areas with lim-
ited access to rheumatologists, further complicates specialist access for these 
groups. We hypothesized that patients diagnosed and managed by a specialist would have 
more ACR criteria documented, increased likelihood of having recommended laboratory 
testing for SLE performed, as well as increased likelihood of having been treated with 
any medications for SLE. The objective of this study was to identify differences be-
tween primary care and specialist diagnosis and management of SLE in the AI/AN popula-
tion and to determine features associated with specialist diagnosis. 
 
PATIENTS AND METHODS: 
Study Population:  
All individuals in the Indian Health Service (IHS) lupus registry 2009 population were 
included in this study if a physician diagnosis of SLE was documented in the medical 
record. The IHS lupus registry has been described previously.19  Briefly, it is a popu-
lation-based registry developed as a surveillance project within the IHS in partner-
ship with the Centers for Disease Control and Prevention (CDC) with the goal of deter-
mining prevalence (2007) and incidence (2007-2009) of SLE in this population.  The 
registry includes all potential SLE cases residing in communities of interest in three 
IHS administrative Areas: Alaska, Phoenix, and Oklahoma. In 2009, direct rheumatology 
care within the IHS or tribal clinics (i.e., an IHS- or tribal clinic-based specialist 
consultant) was available to patients in the communities included from the Alaska and 
Phoenix areas, but not in Oklahoma.  Field medical record abstraction was performed 
for all potential cases of SLE included in the IHS lupus registry. A standardized data 
dictionary was used, and all available medical records were abstracted through 
12/31/2009 as previously described.19 Abstracted data included the final diagnosis of 
the treating physicians, including any specialist documentation of the final diagno-
sis; data elements necessary for assessing SLE classification criteria sets; laborato-
ry testing for SLE; and the ever-use of medications indicated for the treatment of 
SLE.  Data on other aspects of management of SLE, such as preventive care, were not 
collected given the primary focus of the registry on validating diagnosis of SLE. 
 
This study was reviewed by the Institutional Review Boards (IRBs) of the participating 
regions and considered exempt research by the Alaska Area IRB, Phoenix Area IRB, and 
Oklahoma City Area IRB. Tribal approval was obtained from participating tribal health 
organizations. 
 
Case Definitions: 
SLE Diagnosis: A diagnosis in the medical record by a physician of “SLE” or “SLE plus 
another specified connective tissue disease” was required for inclusion in this study. 
Because the design of this study evaluated the diagnostic criteria documented in the 
chart of each case selected, we did not utilize a validated administrative case defi-
nition for entry into this analysis. For patients evaluated by more than one physician 
with disagreement over final diagnosis of SLE (i.e., one physician stated a final di-
agnosis of SLE, whereas another physician stated a final diagnosis of a different con-
nective tissue disease), the diagnosis was recorded as “SLE plus another specified 
connective tissue disease” and included in the study.  SLE was considered to be diag-
nosed by a specialist if the final diagnosis was made by a rheumatologist, nephrolo-
gist, or dermatologist (or any combination of these three).  SLE was considered to be 
diagnosed by primary care if the final diagnosis was stated by a “family medicine, in-
ternal medicine, pediatrics, or women’s health” provider without any documented visit 
to a specialist confirming the diagnosis in the medical record. If at any time a spe-
cialist confirmed the diagnosis of SLE in the medical record, the diagnosis was con-
sidered to be a specialist SLE diagnosis. If a primary care provider documented a di-
agnosis of SLE and a specialist documented a different diagnosis, the specialist’s di-
agnosis was used as the final diagnosis.  
 
ACR Classification Criteria: Abstracted data included all elements required for con-
firmation of the American College of Rheumatology (ACR) revised criteria for SLE.2 
 
Boston Weighted Criteria: Except for “Persistently Negative Antinuclear Antibodies 
(ANA),” abstracted data included all elements required for confirmation of the Boston 
Weighted SLE Classification criteria.3 ANA in our study was captured as ever positive 
or never positive. If it was negative on multiple occasions, this was captured simply 
as never positive, but the number of tests done was not recorded  
 
Systemic Lupus International Collaborating Clinics (SLICC) Criteria: The SLICC crite-
ria4 were finalized after the IHS lupus registry had completed data collection. The 
following elements of the SLICC criteria were not abstracted and therefore not includ-
ed in this analysis: 1) toxic epidermal necrolysis variant of lupus; 2) maculopapular 
lupus rash; 3) joint tenderness; 4) duration of pleurisy; 5) acute confusional state; 
6) ELISA reference range; 7) degree of anticardiolipin elevation; and 8) CH50. The 
lack of data on these elements led us to be missing a small subset of the information 
needed for four of the clinical criteria (acute cutaneous lupus, arthritis, serositis, 
and neurologic involvement) and to have less detail than recommended for the defini-
tion of three of the immunologic criteria (ANA, antiphospholipid antibody, and low 
complement). The exclusion of these elements is expected to lead to lower sensitivity 
in cases where the excluded elements were present but not captured by our data ab-
straction. 
 
Medication Use: All medications were considered positive if documented use was found 
at any time in the medical record, including either a prescription or documentation of 
use in physician notes. Ever treatment with the following medications was assessed: 
hydroxychloroquine, corticosteroids, methotrexate, azathioprine, mycophenolate mo-
fetil, cyclophosphamide, and rituximab. Dose and duration of therapy were not as-
sessed. Belimumab was not FDA-approved at the time the registry began data collection 
and was not captured. 
 
Laboratory Values: Laboratory studies recommended for evaluation of patients with SLE 
were considered to have been assessed if documentation of any result was present in 
the medical record, either by laboratory or physician note documentation. Laboratory 
tests used in the diagnosis and management of SLE and included in this analysis were: 
complement C3 and C4, ANA, anti-double stranded DNA antibody, urinalysis, and IgM or 
IgG anticardiolipin or antiphospholipid antibodies (ACL). 
 
Demographics: The age of SLE diagnosis was determined based on the earliest date at 
which the diagnosis of SLE was stated by a physician in the medical record.  Disease 
duration was determined by subtracting year of diagnosis as determined by medical rec-
ord abstraction from the study year (2009).  Region was defined as the IHS Area in 
which the patient resided during 2009.  In case of multiple addresses, the address as 
of 7/1/2009 was used. 
 
Statistical Analysis: 
All data analysis was performed using Stata software (version 11.2, Statacorp, College 
Station, TX). Categorical data were analyzed by chi-square or Fisher’s exact tests, as 
appropriate. Continuous variables were compared with two-sample t-tests or Mann-
Whitney tests, as appropriate. Multivariate logistic regression analysis was performed 
to calculate adjusted odds ratios (OR) and 95% confidence intervals (CI) of being di-
agnosed with SLE by a specialist for the following predictor variables: age, gender, 
region (Oklahoma [reference], Alaska or Phoenix), and the documented number of ACR 
criteria (less than four vs. four or more).  In all tests used, a two-sided p-value of 
less than 0.05 was considered statistically significant. 
 
RESULTS: 
Demographic characteristics of the 320 patients are shown in Table 1. Study patients 
were predominantly female. The median age of diagnosis of cases diagnosed by primary 
care was older by about 5 years, and the median disease duration was shorter by about 
4 years when compared to cases diagnosed by a specialist. Most cases diagnosed by a 
primary care provider were from the Oklahoma region. Approximately half of the pa-
tients had a diagnosis of SLE and another connective tissue disease. Of those, the 
most common diagnoses were rheumatoid arthritis (23% and 26% of primary care and spe-
cialist diagnoses, respectively), mixed connective tissue disease (21% and 16%), and 
Sjogren’s syndrome (1% and 4%) (data not shown). Of the 249 patients diagnosed by a 
specialist, 242 (97%) were diagnosed by a rheumatologist alone or by a rheumatologist 
and another specialist (data not shown). Table 2 summarizes the proportion of patients 
diagnosed by primary care and specialist providers who met the different SLE classifi-
cation criteria, as well as the median documented number of ACR criteria. Compared 
with those diagnosed by a primary care provider, patients diagnosed by specialist pro-
viders were more likely to have four or more ACR criteria documented and had a higher 
median number of ACR criteria documented. Similar differences were seen with the Bos-
ton Weighted and SLICC criteria. Table 3 shows the differences in the specific ACR 
criteria met in patients diagnosed by primary care vs. specialist providers. Of the 
eleven ACR classification criteria, only three (antinuclear antibody, discoid rash, 
and neurologic disorder) did not differ significantly between primary care and spe-
cialist groups. 
 
Table 4 shows differences in the ever use of medications for SLE, as well as laborato-
ry tests used in the assessment and management of SLE. Compared with those diagnosed 
by a primary care provider, patients diagnosed by a specialist were more likely to 
have ever used all medications assessed.  The difference was the least significant 
with respect to corticosteroids.  There were fewer than five patients overall who re-
ceived rituximab, thus data on rituximab were excluded from the table.  Primary care 
and specialist groups differed significantly in laboratory assessment of complement 
levels C3 and C4, ANA, anti-double-stranded DNA antibody, and anticardiolipin or an-
tiphospholipid antibodies. 
 
No statistically significant differences were found between patients diagnosed with 
SLE alone versus SLE and another connective tissue disease with respect to age, dis-
ease duration, region of residence, proportion with documentation of meeting ACR cri-
teria, Boston weighted criteria, abridged SLICC criteria, and all three sets of crite-
ria (data not shown). Patients with SLE and another connective tissue disease were 
more likely to be female (92% vs 84%, p=0.033), to have met at least one set of crite-
ria (89% vs 80%, p=0.035) and to have ever received hydroxychloroquine (88% vs 73%, p 
=0.001) and methotrexate (58% vs 19%, p<0.001). 
 
Predictors of specialist diagnosis of SLE were assessed using multivariate logistic 
regression and are presented in Table 5. There was no statistically significant asso-
ciation of specialist diagnosis with age or gender. Patients residing in either the 
Alaska or Phoenix region or those with documentation of four or more ACR criteria were 
more likely to have a specialist diagnosis of SLE. 
 
DISCUSSION:  
In this study using data from the IHS lupus registry, a population-based registry of 
AI/AN people with SLE diagnosed by any provider, we found differences between primary 
care and specialist diagnosis and management of SLE. A specialist diagnosis of SLE was 
associated with increased likelihood of fulfilling the ACR and other classification 
criteria, a higher median number of documented ACR criteria, higher likelihood of hav-
ing had recommended laboratory testing for SLE, and a higher likelihood of ever having 
been treated with hydroxychloroquine. 
 
Even in areas of relatively high prevalence SLE is an uncommon disease. Primary care 
providers may not diagnose or manage many patients with SLE in their practices.  Com-
pounding issues with disease familiarity are the complex classification criteria and 
variable presentations and courses of patients with SLE. For these reasons, all pa-
tients suspected of having SLE would ideally be evaluated by a physician familiar with 
the diagnosis and management of the disease, typically a rheumatologist. Yet for some 
patients from rural populations, access to specialist care, including rheumatology, 
remains limited.21 Access to rheumatology specialty care also may be restricted in oth-
er populations with limited access to health care, given the limited supply and uneven 
distribution of rheumatologists in the United States.18 In this study, the majority of 
patients diagnosed by primary care providers (~80%) resided in an area without direct 
access to IHS or tribal clinic-based rheumatology consultation services at the time 
the registry was created. This suggests that when specialists are more available, they 
are included in the diagnosis of SLE. 
 
Management of SLE is often complex. Providers must distinguish disease activity from 
damage, as well as recognizing the more urgent need for aggressive therapy in the set-
ting of organ or life-threatening disease. Compounding this complexity is the propen-
sity for atypical presentation within the AI/AN population.22 The 1999 ACR guidelines 
on the referral and management of adults with SLE focus on the importance of early and 
routine specialist involvement in patient care,7 suggesting that the major role of the 
primary care provider is to refer to a specialist early and to monitor patients with 
mild, stable disease. Others have argued the management of even stable SLE should be 
delegated to rheumatologists alone.23   
 
Prior research has revealed differences between specialist and non-specialist manage-
ment of SLE.5,6,24 In Puerto Rico, Molina et al. examined laboratory testing and pre-
scription patterns in patients with SLE seeing a rheumatologist versus seeing a prima-
ry care provider alone and found that rheumatologists were more likely to order anti-
dsDNA and serum complements, but that urinalysis and anticardiolipin antibodies were 
ordered in similar proportions in each group.5 Of note, only 13-14% of patients had 
anticardiolipin antibodies ordered, a smaller proportion than either group in our 
study (21% in primary care and 38% in specialist group).5 Molina et al. also found 
that hydroxychloroquine was more commonly prescribed by rheumatologists than PCPs 
(32.6% vs. 18.5%), but that even among rheumatologists, this prescription rate was 
low.5 Encouragingly, we found that 65% of patients evaluated by a primary care provid-
er had ever received hydroxychloroquine. It is likely that primary care providers are 
less familiar than specialists with the general recommendation for the use of hy-
droxychloroquine in the management of SLE, but the familiarity may differ by setting 
of practice. Lerang et al.24 compared patients managed by rheumatologists to patients 
managed by other internal medicine specialists in Norway and found that those managed 
by rheumatologists were more likely to be treated with hydroxychloroquine (78% vs. 
12%) and to have been tested for antiphospholipid antibodies (94% vs. 68%). These 
findings are similar to our study, although the proportions with favorable management 
differed. 
 
Our study has some limitations. First, the IHS lupus registry, from which these data 
were obtained, was designed to determine the incidence and prevalence of SLE in this 
population, not to assess SLE severity, longitudinal outcomes, or all aspects of qual-
ity of care. Thus, our study does not have measures of disease activity, severity, 
damage, or all potential quality indicators available for analysis.  Medication histo-
ry and laboratory values were assessed based on an “ever-use” or “ever-assessed” ba-
sis, and data on duration or dose of medications or frequency and timing of laboratory 
assessments were not available. Relatedly, because of our design and desired outcomes, 
this study did not us a previously validated administrative definition of SLE to iden-
tify cases within the national IHS database. Second, this study relied on information 
in the medical record to determine if, and by what means, a specialist or primary care 
provider had ever made the diagnosis of SLE. Although a detailed medical record ab-
straction was performed for each patient, it is possible some patients considered here 
as primary care SLE diagnoses did in fact receive an in-person, specialist consulta-
tion for which documentation was not available in the medical records.  This could 
possibly have occurred outside the IHS health care system. Alternately, an undocument-
ed telephone consultation between the primary care provider and a rheumatologist or 
other specialist could have occurred. Of note, it was not possible to determine how 
many patients within the IHS Lupus Registry sought care outside the IHS.  When availa-
ble in the IHS medical record, outside specialist medical records were included in 
this study. Documentation of patient history and physical exam findings formed the ba-
sis of much of our analysis. Specialists, who presumably would be more familiar with 
classifying SLE, may be more likely to specifically mention the features associated 
with SLE classification criteria in their medical record documentation. In addition, 
it is possible that primary care physicians refer patients meeting a greater number of 
ACR criteria at a higher rate than those patients who have fewer criteria present and 
possibly milder disease. Third, in the medical record abstraction for this study, pa-
tients with a diagnosis of SLE and a diagnosis of another connective tissue disease 
were included in this study as SLE patients. The most common other diagnoses were 
rheumatoid arthritis and mixed connective tissue disease, suggesting that these were 
patients with arthritis or other features of an overlap syndrome as a component of 
their disease. In most of these cases, the laboratory testing and medications used 
would be similar to patients with SLE alone, but the inclusion of patients with other 
connective tissue diseases may have affected our results. Other similar studies did 
not specifically exclude patients with other connective tissue disease5,24 and our re-
sults were comparable to those studies, suggesting that this limitation did not have a 
major impact on our study. Furthermore, we did not find any statistically significant 
differences between the SLE alone and SLE and other connective tissue disease groups, 
other than a higher proportion ever treated with both methotrexate and hydroxychloro-
quine in the SLE and other connective tissue disease group, possibly driven by arthri-
tis. Fourth, because “ever-use” or “ever-tested” was recorded to assess medications 
and laboratory testing, the intent of prescriber may not have been the treatment of 
SLE. For some of the less SLE-specific medications or tests (such as corticosteroids 
and urinalysis), it is possible that these were given or performed for a different 
reason. Because we were using previously collected registry data for this study, we 
were not able to distinguish the rationale for treatment or testing. Despite these 
limitations, the use of “real-world” data from a population-based registry where some 
patients do not have access to specialists is a significant strength of this study and 
allows us to address questions that cannot be addressed in a university-based cohort 
of SLE patients.  
 
Our study shows significant differences in the diagnosis and management of systemic 
lupus erythematosus between specialist and primary care providers. Specific differ-
ences found were the proportion of patients meeting classification criteria, ever-use 
of medications for SLE, and ever-testing for recommended lupus laboratory studies. The 
majority of patients diagnosed with SLE by a primary care provider resided in communi-
ties without direct access to specialist care, suggesting that patients with SLE are 
referred to specialists when available. For populations with limited access to spe-
cialist care, our findings suggest that research should focus on improving access to 
specialists or providing additional support to primary care providers in the diagnosis 
and management of SLE. 
 
  
Key Messages:  
• Specialist diagnosis is associated with an increased likelihood of meeting 
classification criteria for SLE. 
• Specialist diagnosis is associated with increased use of recommended medica-
tions and laboratory tests for SLE. 
• Increased access to specialists and primary care provider education on SLE are 
both recommended. 
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TABLES:  
 
 Table 1: Demographics of SLE Patients by Diagnosing Provider 
 
 Diagnosed by 
Primary Care 
Diagnosed by Spe-
cialist 
 
 n = 71 n = 249 p-value 
Sex, % female 89% 88% 0.86 
Age at diagnosis, years, median 43.5 38.1 0.001 
Duration of SLE in 2009, years, median 5.4 9.7 0.017 
Diagnosis  
   SLE alone, % 
   SLE and other CTD, % 
 
52% 
48% 
 
42% 
58% 
 
0.137 
Region 
   Alaska, % 
   Oklahoma, % 
   Phoenix, % 
 
9% 
80% 
11% 
 
44% 
12% 
44% 
 
<0.001 
 
 
 
 
 
 
  
Table 2: Classification Criteria Met by SLE Patients Diagnosed by Diagnosing Provider 
 
  
Diagnosed by 
Primary Care 
Diagnosed 
by Specialist  
Criteria  n = 71 n = 249 p-value 
Number of ACR criteria documented, median 
(min, max)  2 (0,6) 5 (1,9) <0.001 
Met 4 or more ACR criteria, %  23% 79% <0.001 
Met Boston Weighted criteria, %  32% 82% <0.001 
Met Abridged SLICC criteria, %  35% 83% <0.001 
Met 1 or more set of criteria (ACR, Boston, 
and/or SLICC), %  56% 93% <0.001 
Met all 3 sets of criteria (ACR, Boston, and 
SLICC), %  23% 76% <0.001 
 
 
 
  
Table 3: Proportion of patients diagnosed by primary care providers vs. specialists 
meeting each individual ACR criterion, in order from most to least common by primary 
care provider.a 
 
 Diagnosed by 
Primary Care 
Diagnosed by 
Specialist  
Criterion n = 66 n = 249 p-value 
Antinuclear antibody 88% 94% 0.091 
Hematologic disorder 59% 82% <0.001 
Arthritis 33% 70% <0.001 
Immunologic disorder 32% 59% <0.001 
Malar rash 18% 34% 0.015 
Serositis 17% 43% <0.001 
Photosensitivity 11% 49% <0.001 
Renal disorder 11% 33% <0.001 
Oral Ulcers 3% 35% <0.001b 
Discoid rash 2% 8% 0.091b 
Neurologic disorder 0% 3% 0.212b 
 
 
 
 
a. Excludes patients with diagnosis of SLE who met 0 ACR criteria (n=5 diagnosed 
by primary care provider and 0 diagnosed by specialist). 
b. Denotes p-value obtained by Fisher’s exact testing  
Table 4: Ever use of medications and laboratory testing in SLE patients diagnosed by 
primary care provider vs. specialist 
 
 Diagnosed by 
Primary Care 
Diagnosed by Spe-
cialist 
 
 n = 71 n =249 p-value 
Medication    
Hydroxychloroquine, % 65% 86% <0.001 
Corticosteroids, % 75% 85% 0.039 
Methotrexate, % 20% 47% <0.001 
Azathioprine 11% 25% 0.012 
Mycophenolate mofetil 0% 18% <0.001a 
Cyclophosphamide 0% 7% 0.017 a 
Laboratory Testing    
C3, ever, % 52% 84% <0.001 
C4, ever, % 52% 83% <0.001 
Antinuclear antibody, ever, % 89% 99% <0.001 a 
Urinalysis, ever, % 97% 96% 0.74 a 
Anti-dsDNA testing, ever, % 73% 93% <0.001 
ACL testing, ever, % 21% 38% 0.01 
 
 
 
 
a. Denotes p-value obtained by Fisher’s exact testing 
  
Table 5: Multivariate associations with specialist diagnosis of SLE 
Predictor Variable OR 95% CI p-value 
Age 0.96 0.95, 1.00 0.056 
Gender    
    Malea (base)   
    Female 1.14 0.36, 3.57 0.83 
Region:    
    Oklahoma b (base)   
    Alaska 20.9 7.8, 55.9 <0.001 
    Phoenix 12.6 5.1, 31.0 <0.001 
Number of ACR SLE criteria     
     Less than 4 b (base)   
     4 or more 5.4 2.5, 11.6 <0.001 
 
 
 
 
a. Values are adjusted odds ratio (95% confidence interval).  Odds ratios are 
from multivariate models regressing the outcome of specialist diagnosis of SLE 
on all listed variables.  Age is analyzed as a continuous variable, while all 
other variables are categorical. 
b. Reference category. 
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